NASDAQ:CSBR - Champions Oncology Stock Price, News & Analysis

$5.89
+0.05 (+0.86 %)
(As of 08/20/2019 04:00 PM ET)
Today's Range
$5.75
Now: $5.89
$5.90
50-Day Range
$5.63
MA: $6.97
$8.32
52-Week Range
$5.20
Now: $5.89
$17.90
Volume24,700 shs
Average Volume44,318 shs
Market Capitalization$68.44 million
P/E Ratio589.00
Dividend YieldN/A
Beta1.02
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CSBR
CUSIPN/A
Phone201-808-8400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$27.07 million
Cash Flow$0.0602 per share
Book Value$0.19 per share

Profitability

Net Income$130,000.00

Miscellaneous

Employees92
Market Cap$68.44 million
Next Earnings Date9/12/2019 (Estimated)
OptionableNot Optionable

Receive CSBR News and Ratings via Email

Sign-up to receive the latest news and ratings for CSBR and its competitors with MarketBeat's FREE daily newsletter.


Champions Oncology (NASDAQ:CSBR) Frequently Asked Questions

What is Champions Oncology's stock symbol?

Champions Oncology trades on the NASDAQ under the ticker symbol "CSBR."

How were Champions Oncology's earnings last quarter?

Champions Oncology Inc (NASDAQ:CSBR) issued its quarterly earnings results on Monday, July, 15th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.03 by $0.05. The biotechnology company earned $7.72 million during the quarter, compared to analyst estimates of $6.60 million. Champions Oncology had a net margin of 0.47% and a return on equity of 7.16%. View Champions Oncology's Earnings History.

When is Champions Oncology's next earnings date?

Champions Oncology is scheduled to release their next quarterly earnings announcement on Thursday, September 12th 2019. View Earnings Estimates for Champions Oncology.

What guidance has Champions Oncology issued on next quarter's earnings?

Champions Oncology updated its FY 2020 earnings guidance on Monday, July, 15th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $31.127-35.187 million, compared to the consensus revenue estimate of $31 million.

What price target have analysts set for CSBR?

2 brokerages have issued 1 year price objectives for Champions Oncology's shares. Their predictions range from $17.00 to $17.00. On average, they expect Champions Oncology's share price to reach $17.00 in the next year. This suggests a possible upside of 188.6% from the stock's current price. View Analyst Price Targets for Champions Oncology.

What is the consensus analysts' recommendation for Champions Oncology?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Champions Oncology in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Champions Oncology.

What are Wall Street analysts saying about Champions Oncology stock?

Here are some recent quotes from research analysts about Champions Oncology stock:
  • 1. According to Zacks Investment Research, "Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company's Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments. This technology can evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents. Champions Oncology, Inc. is based in Baltimore, Maryland. " (7/25/2019)
  • 2. National Securities analysts commented, "Low risk way to invest in the development of oncology drugs: Champions Oncology (CSBR) sells products and services to pharmaceutical and biotechnology customers to help them quickly eliminate non-promising drugs, and determine the proper indications, dosage, and patient sub-populations for promising drug candidates. We believe that the company will continue to benefit from the expanding pipeline of oncology drugs.

    Sustained profitability: Champions reported two consecutive profitable quarters in F1Q19 and F2Q19. We believe that CSBR will continue to remain profitable in the second half of F2019 based on revenue growth of 34.1%, a rebound in gross margins to over 50%, and a solid control of operating expenses. In F2020, we project that revenues will grow by 22.7%, and operating margins will reach over 12.3% (compared to 5.3% in FY 2019) resulting in GAAP net income of $3.9 million ($0.27 EPS), up from $1.4 million ($0.10 EPS) in F2019.

    Expanding Cash Flow/Solid Balance Sheet: We believe that higher profitability will translate into cash flow from operations of $1.2 million in F2019 and $5.2 million in F2020. Concurrently, we expect cash will reach $2.3 million at the end of F2019 and $7.7 million at the end of F2020. Further, we anticipate CSBR will continue to remain debt-free and will not fund its growth plans through external financing

    Valuation: We believe that Champions is under-valued based on our price target of $17 a share. A discounted cash flow model would yield a value of $18.00 a share based on a discount rate of 10.8% and a terminal value of $12.5 a share, by our estimates. We assume that the company will start paying taxes in 2024, and will generate free cash flow of over $37 million in F2028. Based on an Enterprise Value to Sales multiple of 6x calendar 2020 revenues of $37.0 million, this would peg shares at a $16.00 valuation. Our $17 price target reflects an average of these two valuation methods. Our multiple reflects a slightly premium to small, fast growing life sciences companies that offer proprietary products and services for the oncology market.
    " (2/27/2019)

Has Champions Oncology been receiving favorable news coverage?

Press coverage about CSBR stock has trended positive this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Champions Oncology earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the near future. View News Stories for Champions Oncology.

Who are some of Champions Oncology's key competitors?

What other stocks do shareholders of Champions Oncology own?

Who are Champions Oncology's key executives?

Champions Oncology's management team includes the folowing people:
  • Dr. Ronnie Morris, CEO & Director (Age 53)
  • Mr. David Barry Miller, Chief Financial Officer (Age 50)
  • Dr. Philip P. Breitfeld, Chief Strategy & Innovation Officer and Director (Age 66)
  • Mr. Mark Weinstein, Chief Information Officer
  • Mr. Bruce Ruggeri, Chief Scientific Officer

Who are Champions Oncology's major shareholders?

Champions Oncology's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Cadence Capital Management LLC (2.28%), Renaissance Technologies LLC (1.55%), Wells Fargo & Company MN (1.28%), Ingalls & Snyder LLC (1.26%), Essex Investment Management Co. LLC (1.19%) and BlackRock Inc. (1.18%). Company insiders that own Champions Oncology stock include Daniel Newman Mendelson, Joel Ackerman and Ronnie Morris. View Institutional Ownership Trends for Champions Oncology.

Which institutional investors are selling Champions Oncology stock?

CSBR stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, Ingalls & Snyder LLC, Renaissance Technologies LLC, Invesco Ltd. and Cadence Capital Management LLC. Company insiders that have sold Champions Oncology company stock in the last year include Daniel Newman Mendelson and Joel Ackerman. View Insider Buying and Selling for Champions Oncology.

Which institutional investors are buying Champions Oncology stock?

CSBR stock was acquired by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Essex Investment Management Co. LLC, Wedge Capital Management L L P NC, BlackRock Inc., Alambic Investment Management L.P. and Susquehanna International Group LLP. View Insider Buying and Selling for Champions Oncology.

How do I buy shares of Champions Oncology?

Shares of CSBR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Champions Oncology's stock price today?

One share of CSBR stock can currently be purchased for approximately $5.89.

How big of a company is Champions Oncology?

Champions Oncology has a market capitalization of $68.44 million and generates $27.07 million in revenue each year. The biotechnology company earns $130,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. Champions Oncology employs 92 workers across the globe.View Additional Information About Champions Oncology.

What is Champions Oncology's official website?

The official website for Champions Oncology is http://www.championsoncology.com/.

How can I contact Champions Oncology?

Champions Oncology's mailing address is One University Plaza Suite 307, Hackensack NJ, 07601. The biotechnology company can be reached via phone at 201-808-8400 or via email at [email protected]


MarketBeat Community Rating for Champions Oncology (NASDAQ CSBR)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  269
MarketBeat's community ratings are surveys of what our community members think about Champions Oncology and other stocks. Vote "Outperform" if you believe CSBR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSBR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2019 by MarketBeat.com Staff

Featured Article: What is a Stop Order?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel